Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

OncoImmunology

Volumn 4, Issue 6, 2015, Pages

  Calcinotto, Arianna ^a,b   Ponzoni, Maurilio ^a   Ria, Roberto ^c   Grioni, Matteo ^a   Cattaneo, Elena ^a   Villa, Isabella ^a   Bertilaccio, Maria Teresa Sabrina ^a   Chesi, Marta ^d   Rubinacci, Alessandro ^a   Tonon, Giovanni ^a   Bergsagel, P Leif ^d   Vacca, Angelo ^c   Bellone, Matteo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Macrophages; Multiple myeloma; Smoldering multiple myeloma; T cells

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR BB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MONOCLONAL IMMUNOGLOBULINEMIA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY; PROTEIN ELECTROPHORESIS; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

EID: 84944474717     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1008850     Document Type: Article

References (49)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6:249-74; PMID:21261519; http://dx.doi.org/10.1146/annurev-pathol-011110-130249
2. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64:814-26; PMID:645746; http://dx.doi.org/ 10.1016/0002-9343(78)90522-3
3. Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res 2013; 19:985-94; PMID:23224402; http://dx.doi.org/ 10.1158/1078-0432.CCR-12-2922
4. Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365:474-5; PMID:21812699; http://dx.doi.org/ 10.1056/NEJMc1106428
5. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012; 9:135-43; PMID:22349016; http:// dx.doi.org/10.1038/nrclinonc.2012.15
6. Bergsagel PL, Kuehl WM. Degree of focal immunoglobulin heavy chain locus deletion as a measure of Bcell tumor purity. Leukemia 2013; 27:2067-8; PMID:23644420; http://dx.doi.org/10.1038/leu. 2013.139
7. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J, Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106:296-303; PMID:15755896; http:// dx.doi.org/10.1182/blood-2005-01-0034
8. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324
9. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx. doi.org/10.1056/NEJMra1011442
10. Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, Rosinol L, Paiva B, Palomera L, Bargay J et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013; 369:438-47; PMID:23902483; http://dx.doi.org/10.1056/NEJMoa1300439
11. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000; 97:228-33; PMID:10618400; http://dx. doi.org/10.1073/pnas.97.1.228
12. Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Tamizhmani K, Garbitt VM, Riggs DL, Brents LA, Roschke AV et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly superenhancers to dysregulate MYC expression in multiple myeloma. Leukemia 2014; 28:1725-35; PMID:24518206; http://dx.doi.org/10.1038/ leu.2014.70
13. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13:167-80; PMID:18242516; http://dx.doi. org/10.1016/j.ccr.2008.01.007
14. Kuehl WM. Modeling multiple myeloma by AIDdependent conditional activation of MYC. Cancer Cell 2008; 13:85-7; PMID:18242508; http://dx.doi.org/ 10.1016/j.ccr.2008.01.022
15. Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 2013; 97:313-23; PMID:23456262; http://dx.doi. org/10.1007/s12185-013-1291-2
16. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, Pacini R, Alunni C, Natali-Tanci L, Ugolini B et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95:2084-92; PMID:10706878
17. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28:536-42; PMID:11740806; http://dx. doi.org/10.1016/S0093-7754(01)90021-1
18. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85:800-5; PMID:10942925
19. Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P, Kyriakou DS. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res 2004; 28:259-66; PMID:14687621; http://dx.doi.org/10.1016/S0145-2126(03)00261-3
20. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-9; PMID:2479986; http://dx.doi.org/10.1126/ science.2479986
21. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32:593-604; PMID:20510870; http://dx.doi.org/ 10.1016/j.immuni.2010.05.007
22. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007; 28:519-24; PMID:17981504; http://dx.doi.org/10.1016/j.it.2007.09.004
23. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93:3064-73; PMID:10216103
24. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111-6; PMID:10955791
25. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8:2210-6; PMID:12114422
26. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31; PMID:7584949; http://dx.doi.org/10.1038/nm0195-27
27. Bhutani M, Turkbey B, Tan E, Kemp TJ, Pinto LA, Berg AR, Korde N, Minter AR, Weiss BM, Mena E et al. Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia 2014; 28:413-6; PMID:24045500; http://dx.doi.org/ 10.1038/leu.2013.268
28. Ostad M, Andersson M, Gruber A, Sundblad A. Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma. Blood 2008; 111:2725-32; PMID:18156498; http://dx.doi.org/10.1182/blood-2006-11-056242
29. Sharma A, Khan R, Joshi S, Kumar L, Sharma M. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma 2010; 51:920-7; PMID:20367137; http://dx.doi.org/ 10.3109/10428191003699563
30. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L, De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114:901-14; PMID:19383967; http://dx.doi.org/ 10.1182/blood-2009-01-200931
31. He H, Xu J, Warren CM, Duan D, Li X, Wu L, Iruela-Arispe ML. Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood 2012; 120:3152-62; PMID:22919031; http://dx.doi.org/10.1182/blood-2012-04-422758
32. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19:512-26; PMID:21481792; http://dx.doi.org/10.1016/j.ccr.2011.02.005
33. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy druginduced apoptosis. Blood 2009; 114:3625-8; PMID:19710503; http://dx.doi.org/10.1182/blood-2009-05-220285
34. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006; 25:4257-66; PMID:16518413; http://dx.doi.org/ 10.1038/sj.onc.1209456
35. Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood 2014; 123:3305-15; PMID:24723682; http://dx.doi.org/10.1182/blood-2014-02-554071
36. Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol 2012; 158:336-46; PMID:22583117; http://dx. doi.org/10.1111/j.1365-2141.2012.09154.x
37. Ribatti D. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. Immunol Lett 2013; 152:83-8; PMID:23685256; http://dx.doi.org/10.1016/j.imlet. 2013.05.003
38. Berardi S, Ria R, Reale A, De Luisi A, Catacchio I, Moschetta M, Vacca A. Multiple myeloma macrophages: pivotal players in the tumor microenvironment. J Oncol 2013; 2013:183602; PMID:23431298; http:// dx.doi.org/10.1155/2013/183602
39. Scavelli C, Nico B, Cirulli T, Ria R, Di Pietro G, Mangieri D, Bacigalupo A, Mangialardi G, Coluccia AML, Caravita T et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2007; 27:663-74; PMID:17667938; http:// dx.doi.org/10.1038/sj.onc.1210691
40. Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26:351-62; PMID:11006136; http://dx.doi.org/10.1053/ ctrv.2000.0188
41. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7:575-83; PMID:11329059; http://dx.doi.org/10.1038/87904
42. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011; 117:5573-81; PMID:21441462; http://dx.doi.org/10.1182/blood-2011-01-270140
43. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15:1274-6; PMID:11480571; http://dx.doi.org/ 10.1038/sj.leu.2402183
44. Martin A, Garcia-Sanz R, Hernandez J, Blade J, Suquia B, Fernandez-Calvo J, Gonzalez M, Mateo G, Orfao A, San Miguel JF. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol 2002; 118:239-42; PMID:12100153; http://dx.doi. org/10.1046/j.1365-2141.2002.03549.x
45. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-9; PMID:12506164; http://dx.doi.org/10.1200/ JCO.2003.03.139
46. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113:1588-95; PMID:18683218; http:// dx.doi.org/10.1002/cncr.23783
47. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA et al. Long-term results of singleagent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol 2010; 85:737-40; PMID:20730790; http://dx.doi.org/ 10.1002/ajh.21821
48. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88:226-35; PMID:23440663; http:// dx.doi.org/10.1002/ajh.23390
49. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun; 121(5):749-57; PMID:12780789; http://dx.doi.org/10.1046/j.1365-2141.2003.04355.x